Spelling suggestions: "subject:"AIDS vaccine""
41 |
The characterisation and expression of HIV-1 subtype C gagSampson, Candice Corene January 2002 (has links)
Thesis (MScMedSc) -- University of Stellenbosch, 2002. / ENGLISH ABSTRACT: The gag gene of HIV-1 encodes for one of the major structural proteins, which
contains several conserved cytotoxic T cell (CTL) epitopes. Gag specific CTL
responses are important in controlling viral load during acute infection and
asymptomatic stages of the infection. Currently, only one complete South African
HIV-1 subtype C gag sequence has been published. The first aim of this study
was to characterise the complete gag gene of 15 HIV-1 subtype C isolates, to be
used as a set of reference sequences in the design of a South African HIV-1
subtype C vaccine.
Fifteen HIV-1 subtype C isolates selected for this study, were isolated during 1998
and 1999 from the HIV-1 positive patients attending the Infectious Disease Clinic at
Tygerberg Hospital. The gag gene of these isolates was amplified by PCR, cloned
into mammalian expression vectors and sequenced. Restriction digest analyses as
well as phylogenetic analyses were performed on the sequencing data. Previously
published mutational analyses and CTL epitopes were compared to the predicted
amino acid sequences of the gag clones.
Sequences of 23 complete gag genes representing the 15 HIV-1 subtype C
isolates as well as one complete sequence of an HIV-1 subtype B isolate were
compiled. Subtyping by restriction fragment length polymorphism (RFLP) would
have correctly identified 14 of the 15 subtype C isolates as subtype C and one as
unidentifiable. The subtype B isolate would have also been correctly identified.
Phylogenetic analyses showed that our subtype C isolates clustered with reference
subtype C strains from various countries, including Botswana, India, Israel,
Tanzania and Zambia. Strains from Ethiopia and Brazil formed a separate subtype
C cluster. The diversity between our isolates was comparable to the diversity seen
between all the HIV-1 subtype C strains. Comparisons of previously published
mutational analyses and CTL epitopes to the predicted amino acid sequences of the gag clones, showed conservation in most of the clones throughout the
sequence.
A second aim was to establish transfection and Western Blot techniques in our
laboratory for use in future studies. An in vitro transcription! translation assay was
performed on the gag clones and the protein producing clones were used to
transfect mammalian cells using electroporation. A Western blot was then used to
screen for Gag protein expression in the transfected cell Iysates.
The in vitro transcription! translation assay showed that seven of the 23 clones
could produce a protein of -55 kDa in size. Four out of the seven of these clones
gave a weak expression of a-55 kDa protein after transfection in a mammalian
cell line. Since the completion of the experimental work of this study, other cloned
HIV-1 genes have successfully been transfected into mammalian cells using the
electroporation technique and the proteins produced were screened for by Western
blot.
To conclude with; the native form of the gag gene does not elicit strong expression
of the protein, but studies have shown that expression can be improved by
sequence-modification of the gag nucleotide sequence. Due to the conservation of
gag, the sequence of any subtype C strain can be used for the development of a
Southern African vaccine. / AFRIKAANSE OPSOMMING: Die HIV-1 gag geen kodeer vir een van die hoof strukturele proterene en bevat
verskeie sitotoksiese T-limfosiet epitope. Gag spesifieke sellulere immuun respons
is belangrik vir die beheer van virale lading tydens akute infeksies en tydens
asimptomatiese fases van die infeksie. Tans is slegs een volledige Suid
Afrikaanse HIV-1 subtipe C nuklerensuur volgorde gepubliseer. Die eerste doel
van hierdie studie was om die volledige gag geen van 15 HIV-1 subtipe C isolate te
karakteriseer, om gebruik te word as In stel verwysings nukleiensuur volgordes, vir
die ontwerp van In Suid Afrikaanse HIV-1 subtipe C entstof.
Die 15 HIV-1 subtipe C isolate wat vir hierdie studie geselekteer is, is tydens 1998
en 1999 ge·lsoleer vanaf HIV-1 positiewe pasiente wat die Infeksiesiekte Kliniek,
Tygerberg Hospitaal bygewoon het. Die gag geen van hierdie isolate is
geamplifiseer deur PKR, gekloneer in soogdier ekspressie vektore en die
nukleiensuur volgorde is bepaal. Die nuklerensuur volgorde is gebruik in restriksie
ensiem analises asook filogenetiese analises. Reeds gepubliseerde mutasie
analises en limfosiet epitope is met die voorspelde aminosuur volgorde van die gag
klone vergelyk.
Die nukleiensuur volgordes van die 23 volledige gag gene wat die 15 HIV-1
subtipe C isolate verteenwoordig, asook een volledige nukleiensuur volgorde van
een HIV-1 subtipe B isolaat, is saamgestel. Subtipering deur middel van restriksie
fragment lengte polimorfisme (RFLP) sou 14 uit die 15 subtipe C isolate korrek
qerdentifiseer het, maar sou een nie kon identifiseer nie. RFLP sou ook die
subtipe B isolaat korrek qerdentifiseer het. Filogenetiese analises het gewys dat
ons subtipe C isolate met die verwysings subtipe C stamme van verskeie lande,
insluitend Botswana, lndie, Israel, Tanzania en Zambie groepeer. Stamme van
Ethiopie en Brasilie het In aparte subtipe C groep gevorm. Die diversiteit tussen
ons isolate was vergelykbaar met die diversiteit tussen al die subtipe C stamme.
Vergelykings van gepubliseerde mutasie analises en limfosiet epitope met die voorspelde aminosuur volgorde van die gag klone, het konservasie in meeste van
die klone, deur die hele nukleiensuur volgorde, getoon.
Die tweede doel was om die metodes van transfeksie en Westerse klad in ons
laboratorium tot stand te bring. In vitro transkripsie/ translasie toetse is gedoen op
die gag klone en die proteten produserende klone is gebruik om soogdierselle te
transfekteer deur gebruik te maak van elektroporasie. In Westerse klad is toe
gebruik om vir Gag proterenuitdrukkinq in die sellisate te toets.
Die in vitro transkripsie/ translasie toets het getoon dat sewe uit 23 klone, In
proteren van -55 kDa kon produseer. Vier uit die sewe van hierdie klone het In
-55 kDa proteren swak uitgedruk na transfektering van soogdier selle. Sedert die
voltooiing van die eksperimentele werk van hierdie stud ie, is ander gekloneerde
HIV-1 gene suksesvol in soogdierselle getransfekteer met die gebruik van
elektroporasie en die proterene is met In Westerse klad aangetoon.
Ten slotte: die natuurlike vorm van die gag geen ontlok nie In sterk ekspressie van
die proteren nie, maar ander studies het wei aangetoon dat die ekspressie verbeter
kan word met modifikasie van die gag nukleiensuur volgorde. As gevolg van die
konservasie van gag, kan die nuklerensuur volgorde van enige subtipe C stam
gebruik word vir die ontwikkeling van In Suider Afrikaanse entstof. / The Poliomyelitis Research Foundation / The South African AIDS Vaccine Initiative / Harry Crossley Foundation
|
42 |
Characterisation of the HIV-1 subtype C Env gene and the expression of the Env protein from selected isolates in mammalian cellsDe Villiers, Tania 03 1900 (has links)
Thesis (MSc)--Stellenbosch University, 2000. / ENGLISH ABSTRACT: At the end of 2002, human immunodeficiency virus (HIV) had infected 42 million people
worldwide. The morbidity and mortality rate, as well as the epidemic proportions of the
disease have led to concentrated scientific efforts to reveal the disease's pathogenesis
and develop effective preventative and treatment measures. Advances have been made
to inhibit viral replication by suppressing the virus' ability to replicate by developing antiretroviral
treatments, although development of a save and effective vaccine is the only
way to stem the pandemic. Advances in vaccine design, animal models and clinical
research have led to the creation of promising candidate vaccines to counter this
rampage, but most of these vaccines entering phase I-III clinical trials are based mainly
only subtype B genomes. HIV-1 subtype C is the most commonly transmitted subtype
worldwide, and is the predominant subtype in India, China, East and Southern Africa. A
subtype C vaccine is critical for the developing nations such as South Africa, where antiretroviral
therapies are largely unaffordable. The envelope gene (env) is an attractive
target as immunogen to be included in a HIV vaccine. The envelope protein (Env) elicits
neutralising antibodies and cytotoxic T-Iymphocyte (CTl) responses. This protein will
therefore be useful in creating a humoral and cellular immune response in the host. A
shortage in characterised subtype C env gene sequences from South Africa was
recognised, and this study focussed on the characterisation of generated sequences, as
well as the expression of selected env genes. These immunogens were created for
possible use in a prime-boost vaccine modality. The env genes from recent circulating
strains in South Africa were amplified by polymerase chain reaction (PCR). The genes
were then cloned for sequencing and expression purposes. Phylogenetic relationships
were determined by comparing the sequences to reference subtype strains and subtype
C strains. Expression of the genes was assessed by Western Blot in 293 cells with HIV-
1 positive patient sera.
Sequence analysis showed a more conserved third variable (V3) loop in South African
subtype C sequences, with a more variable region downstream from the loop. The
crown sequence (GPGQ) and positions of uncharged or negatively charged residues in the V3 loop indicated a non-syncytium-inducing (NSI) phenotype for the isolates.
Phylogenetic analysis showed the sequences to all belong to the C subtype, and further
that the sequences were not recombinant, which was confirmed by recombination
analysis. The intersample diversity observed for strains from South Africa was
significantly higher than distances observed to the subtype C consensus sequence. The
South African sequences were distributed across several subclusters in a subtype C
phylogenetic tree, highlighting the concept that these infections represent a more
longstanding epidemic with multiple introductions from different geographic areas.
Western Blot with HIV-1 positive patient sera showed the expression of uncleaved
gp160 Env proteins, which were Rev dependent.
This study has generated much needed subtype C South African env gene sequences
that can be used as basis for modification for use as immunogens in a South African
vaccine. / AFRIKAANSE OPSOMMING: Teen die einde van 2002 was 42 miljoen mense wêreldwyd geïnfekteer met die
menslike immuniteitsgebrekvirus (MIV). Die dode- en sterfte syfers, asook die skaal van
die epidemie, het gelei tot 'n wetenskaplike poging om die siekte se patogenese te
openbaar en om effektiewe voorkomende en terapeutiese middels te ontwikkel.
Vordering is reeds gemaak om die virus se replikasie te hinder deur die ontwerp van
antivirale middels, alhoewel die ontwikkeling van 'n doeltreffende en veilige entstof die
enigste manier is om die pandemie te stuit. As gevolg van die vordering in entstof
ontwerp, diere modelle en kliniese navorsing is belowende kandidaat entstowwe wat die
infeksie kan teenwerk ontwikkel, maar die meeste van hierdie enstowwe wat vir fase I-III
kliniese proewe gebruik word is gebaseer op subtipe B genome. MIV-subtipe C is
wêreldwide die algemeenste subtipe wat oorgedra word en is die oorheersende subtipe
in lande soos Indië, China, oostelike en suidelike Afrika. 'n Subtipe C entstof word
dringend benodig in ontwikkelende lande soos Suid-Afrika waar antivirale middels
onbekostigbaar is. Die membraangeen is 'n aanloklike teiken om as immunogeen in 'n
MIV entstof te dien. Die membraanproteïen lok neutraliserende teenliggame en
sitotoksiese T-limfosiet reaksies uit. Die proteïen sal dus 'n humorale en sellulêre
immuunrespons in die gasheer ontlok. 'n Tekort aan gekarakteriseerde subtipe C
membraangeen volgordes van Suid-Afrika is opgemerk, en dus fokus hierdie studie op
die karakterisering van gegenereerde volgordes, asook die uitdrukking van
geselekteerde membraangene. Die immunogene is geskep om moontlik gebruik te word
in 'n stimuleer-versterkingsenstof toedieningstrategie. Die membraangene van onlangs
sirkulerende virusstamme in Suid-Afrika was geamplifiseer deur polimerase
kettingreaksie (PKR). Die gene is daarna gekloneer vir beide volgordebepalings en
uitdrukkingdoeleindes. Filogenetiese verhoudings is uitgewerk deur die volgordes met
verwysingsstamme en subtipe C stamme te vergelyk. Uitdrukking van die gene is
waargeneem in 293 selle deur die Westerse kladtegniek te gebruik met MIV-1 positiewe
pasiëntsera as teenliggaam.
Volgorde-analise het aangetoon dat die derde varieerbare (V3) lus meer gekonserveer
is, en dat die gedeelte wat op die lus volg meer varieerbaar is. Die kroonvolgorde
(GPGQ) asook posisies van ongelaaide of negatief gelaaide aminosure in die V3 lus het
aangedui dat die isolate 'n nie-syncytia induserende fenotipe het. Filogenetiese analise
het aangedui dat al die volgordes subtipe C is en dat die volgordes nie rekombinant is
nie. Dit is ook deur rekombinasie analise bewys. Die inter-monster diversiteit van die
Suid-Afrikaanse volgordes was hoër as die waargenome afstand vanaf die subtipe C
konsensus volgorde. Die Suid-Afrikaanse volgordes is versprei oor verskeie subgroepe
in 'n subtipe C boom, wat die konsep dat hierdie infeksies 'n meer gevestigde epidemie
voorstel waar veelvuldige infeksies met verskillende geografiese oorspronge
plaasgevind het beklemtoon. Die Westerse klad het ongeprosesseerde gp160
membraanproteïne aangetoon wat Rev afhanklik was.
Hierdie studie het hoogs benodigde subtipe C Suid-Afrikaanse volgordes van
membraangene geproduseer. Die volgordes kan as basis dien om die gene te
modifiseer sodat dit gebruik kan word as immunogene in 'n entstof vir Suid-Afrika.
|
43 |
Caracterização fenotípica e funcional de linfócitos T de memória de indivíduos infectados pelo HIV reativos a epitopos T CD4+ derivados de sequências do consenso B do HIV-1 / Phenotypic and functional characterization of memory T lymphocytes from HIV infected individuals reactive to CD4-T epitopes derived from sequences of the HIV-1 B consensusBorgo, Adriana Coutinho 01 March 2010 (has links)
A persistência de células T de memória funcionais é importante para garantir uma imunidade protetora na infecção pelo Vírus da Imunodeficiência Humana (HIV). As células T de memória têm sido subdivididas em memória central (TCM), memória efetora (TEM) e memória efetora altamente diferenciada (TEMRA) com base na expressão de moléculas de superfície como CCR7 e CD45RA, e na capacidade de produzir citocinas e proliferar. Recentemente, identificamos 18 peptídeos derivados de seqüências do consenso B do HIV-1, ligadores de múltiplas moléculas HLA-DR e amplamente reconhecidos por linfócitos T de sangue periférico de pacientes infectados pelo HIV. Diante disso e considerando a importância das células T de memória na manutenção da resposta imune específica, nosso objetivo foi caracterizar fenotípica e funcionalmente as subpopulações de células T de memória de indivíduos infectados pelo HIV envolvidas no reconhecimento in vitro desses epitopos. Foram incluídos 14 indivíduos controles sadios e 61 pacientes HIV+ com contagem de linfócitos T CD4+ maior que 250 células/mm3. Os pacientes HIV+ foram divididos em seis diferentes grupos clínicos de acordo com o estágio da infecção, carga viral (CV) plasmática e uso de terapia anti-retroviral (ART): não progressores por longo tempo (LTNP), avirêmicos em uso de ART (AV-ART), virêmicos em uso de ART (VI-ART), virêmicos sem uso de ART (VI sem ART), virêmicos recéminfectados sem uso de ART (VI-RI) e controladores. Células mononucleares do sangue periférico dos indivíduos do estudo foram estimuladas com o conjunto de peptídeos do HIV-1 e com um conjunto de peptídeos do Citomegalovírus (CMV). A freqüência de células de memória produtoras de IFN- e IL-2 e a proliferação celular antígeno-específica foram detectadas por citometria de fluxo de multiparâmetros. Nossos resultados mostraram que o conjunto de peptídeos do HIV-1 foi capaz de ativar subpopulações funcionais de memória TCM, TEM e TEMRA secretoras de IFN- e IL-2 em 100% dos pacientes HIV+ dos diferentes grupos clínicos. O conjunto de peptídeos do HIV-1 também induziu proliferação das subpopulações de linfócitos T de memória. As freqüências de TEMRA CD4+IFN-+, TEMRA CD4+IFN-+ total, TCM CD8+IFN-+, TCM CD8+IFN-+ total, TEM CD8+IFN-+, TEM CD8+IFN-+ total e TEMRA CD8+IFN-+ correlacionaram-se negativamente com a carga viral do HIV em pacientes virêmicos. Esses dados sugerem que essas subpopulações de memória funcionais são importantes no controle da viremia. Comparando as respostas HIV e CMVespecíficas observamos freqüências mais elevadas de células T de memória produtoras de IL-2, IFN-/IL-2 e IFN- em respostas ao pool de peptídeos do HIV. Esses dados sugerem que esse conjunto de peptídeos derivados de seqüências do HIV-1 ativa respostas polifuncionais de subpopulações de linfócitos T de memória. Nossos resultados mostraram que o conjunto de peptídeos do HIV-1 foi capaz de estimular diferentes subpopulações distintas de linfócitos T de memória produtores de IFN-, IFN-,/IL-2 e IL-2 de indivíduos em diferentes estágios da infecção pelo HIV e sugerem o envolvimento de subpopulações de memória funcionais no controle da viremia. Estes achados fortalecem a possibilidade de uso desses peptídeos em uma formulação vacinal bem-sucedida em humanos / The persistence of functional memory T cell is important to ensure a protective immunity to Human Immunodeficiency Virus (HIV) infection. Memory T cells have been subdivided into central memory (TCM), effector memory (TEM) and highly differentiated effector memory (TEMRA) based on the expression of surface molecules such as CCR7 and CD45RA, and the ability to produce cytokines and proliferate. Recently, we identified 18 peptides derived from B consensus sequences of HIV-1 that bind to multiple HLA-DR molecules and are widely recognized by peripheral blood T lymphocytes from HIV-infected patients. Given this and considering the importance of memory T cells in the maintenance of specific immune response, our objective was to characterize phenotypic and functionally memory T cell subsets from HIV-infected individuals involved in the recognition of these epitopes in vitro. The study included 14 healthy control subjects and 61 HIV+ patients with CD4+ lymphocytes counts higher than 250 cells/mm3. The HIV+ patients were divided into six different clinical groups according to the stage of infection, plasma viral load (VL) and antiretroviral therapy use (ART): long-term non-progressors (LTNP), aviremic under ART (AV-ART), viremic under ART (VI-ART), viremic without using ART (VI without ART), recently infected viremic without using ART (VI-RI) and controllers. Peripheral blood mononuclear cells from study subjects were stimulated with HIV-1 peptide pool and with a cytomegalovirus (CMV) peptide pool. The frequencies of IFN- and IL-2 producing memory cells and antigenspecific cell proliferation were detected by multiparametric flow cytometry. Our results showed that the HIV-1 set of peptides was able to activate TCM, TEM and TEMRA functional memory subsets that secrete IFN- and IL-2 in 100% of the HIV patients from the different clinical groups. The HIV-1 set of peptides also induced memory T lymphocyte subsets proliferation. TEMRA CD4+IFN-+, total TEMRA CD4+IFN-+, TCM CD8+IFN-+, total TCM CD8+IFN-+, total TEM CD8+IFN-+, TEM CD8+IFN-+ and TEMRA CD8+IFN- + frequencies negatively correlated with HIV viral load in viremic patients. These data suggest that these functional memory subsets are important to control the viremia. When comparing the HIV and CMV-specific responses we observed higher frequencies of IL-2, IFN-/IL-2 and IFN- producing memory T cells in response to HIV peptide pool. These data suggest that this set of HIV sequence derived peptides activates polyfunctional response of memory T lymphocyte subsets. Our results showed that the HIV-1 peptide set was able to stimulate different IFN-, IFN-/IL-2 e IL-2 producing memory T lymphocytes from individuals in different stages of HIV infection and suggest the involvement of functional memory subsets in the control of viremia. These findings strengthen the possibility of using these peptides in a successful vaccine formulation in humans
|
44 |
The role of interleukin-10 promoter polymorphisms in HIV-1 susceptibility and primary HIV-1 pathogenesis.Naicker, Dshanta D. January 2007 (has links)
Host genetic factors may partially account for the uneven distribution of HIV infection worldwide. In addition to influencing relative susceptibility to HIV, host genetic factors may also affect the rate of disease progression in persons who are already HIV infected. J.L-10 was previously identified as an AIDS restricting gene (ARG), i.e. human genes with polymorphic variants that influence the outcome of HIV-1 exposure or infection. IL-10 is a Th2 cytokine, with anti-inflammatory properties, and plays a significant role in the regulation of immune responses; this cytokine may also directly influence viral replication. This study focused on the role of genetic polymorphisms in the proximal promoter region of the IL-10 gene on HIV-:eptibility and primary HIV-1 pathogenesis in a South African comprising of women at high risk of HIV-1 infection
In this study 228 black females from the CAPRISA Acute Infection cohort were genotyped for two polymorphisms that naturally occur within the proximal region of the IL-10 promoter, at positions -.1082 and -592 (tracking -819) relative to the transcription start site. DNA samples from study participants were genotyped using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) method, which utilises specifically designed primers to detect single nucleotide polymorphisms. The allele frequencies for the mutant -1082G and -592A variants were 0.3203 and 0.333 respectively.Individuals homozygous for the mutation at the -392 position (AA genotype) were 2.78 times more likely to become HIV infected, compared to those who were homozygous wild type (CC genotype) at the same position (p-value=0.0237). Among those who became HIV infected, we found a hierarchical association between IL-10 promoter variants and HIV-1 plasma viral load or CD4+ T cell counts over the course year of HIV-1 infection. At earlier time points, i.e. 0-3 months post-te -1082GG group had significantly higher median viral loads than the -AA or -1082AG groups (pvalues= <0.0001 and 0.0003 respectively); and the -1082AA group had the highest median CD4'' T cell count compared to the -1082AG or -1082GG groups and this was significant (p-values= 0.0194 and 0.0122 respectively). At 6-12 months post-infection the median viral load of the -1082GG group was lower than -1082AA group, however this was not significant (p-value=0.6767). Analysis of the effect of the -592 polymorphism showed that the -592AA group had a lower median viral load at 0-3 months post-infection compared to the homozygous wild-type group (i.e. -592CC p~value=0.0093); and the median CD4+ T cell count for the -592AA group was significantly higher than the -592CC group (p~ value= 0.0198). At 6-12 months post-infection, the median viral load as well as the median CD4+ T cell count of the -592 A A group were both no longer significantly different to the -592CC group (p-values= 0.644land 0.6461 respectively). Plasma IL-10 expression was not significantly different between the IL-I0 genotypes for any of the polymorphic positions.Overall, these results suggest that polymorphisms within the IL-10 promoter may influence the risk of HIV infection and that they may affect primary HIV-1 pathogenesis. Interestingly, our data suggests that the effect of these polymorphic variants on viral and CD4+ T cell counts may vary according to time post-infection. To our knowledge, this is the first study to suggest that an ARG may have a differential effect on markers of disease progression depending on the phase of infection studied. The mechanisms underlying these observations require further studies and may have important implications for HIV/AIDS pathogenesis and the development of effective vaccine and immunotherapeutic strategies. / Thesis (M.Sc.)-University of KwaZulu-Natal, Pietermaritzburg, 2007.
|
45 |
Caracterização fenotípica e funcional de linfócitos T de memória de indivíduos infectados pelo HIV reativos a epitopos T CD4+ derivados de sequências do consenso B do HIV-1 / Phenotypic and functional characterization of memory T lymphocytes from HIV infected individuals reactive to CD4-T epitopes derived from sequences of the HIV-1 B consensusAdriana Coutinho Borgo 01 March 2010 (has links)
A persistência de células T de memória funcionais é importante para garantir uma imunidade protetora na infecção pelo Vírus da Imunodeficiência Humana (HIV). As células T de memória têm sido subdivididas em memória central (TCM), memória efetora (TEM) e memória efetora altamente diferenciada (TEMRA) com base na expressão de moléculas de superfície como CCR7 e CD45RA, e na capacidade de produzir citocinas e proliferar. Recentemente, identificamos 18 peptídeos derivados de seqüências do consenso B do HIV-1, ligadores de múltiplas moléculas HLA-DR e amplamente reconhecidos por linfócitos T de sangue periférico de pacientes infectados pelo HIV. Diante disso e considerando a importância das células T de memória na manutenção da resposta imune específica, nosso objetivo foi caracterizar fenotípica e funcionalmente as subpopulações de células T de memória de indivíduos infectados pelo HIV envolvidas no reconhecimento in vitro desses epitopos. Foram incluídos 14 indivíduos controles sadios e 61 pacientes HIV+ com contagem de linfócitos T CD4+ maior que 250 células/mm3. Os pacientes HIV+ foram divididos em seis diferentes grupos clínicos de acordo com o estágio da infecção, carga viral (CV) plasmática e uso de terapia anti-retroviral (ART): não progressores por longo tempo (LTNP), avirêmicos em uso de ART (AV-ART), virêmicos em uso de ART (VI-ART), virêmicos sem uso de ART (VI sem ART), virêmicos recéminfectados sem uso de ART (VI-RI) e controladores. Células mononucleares do sangue periférico dos indivíduos do estudo foram estimuladas com o conjunto de peptídeos do HIV-1 e com um conjunto de peptídeos do Citomegalovírus (CMV). A freqüência de células de memória produtoras de IFN- e IL-2 e a proliferação celular antígeno-específica foram detectadas por citometria de fluxo de multiparâmetros. Nossos resultados mostraram que o conjunto de peptídeos do HIV-1 foi capaz de ativar subpopulações funcionais de memória TCM, TEM e TEMRA secretoras de IFN- e IL-2 em 100% dos pacientes HIV+ dos diferentes grupos clínicos. O conjunto de peptídeos do HIV-1 também induziu proliferação das subpopulações de linfócitos T de memória. As freqüências de TEMRA CD4+IFN-+, TEMRA CD4+IFN-+ total, TCM CD8+IFN-+, TCM CD8+IFN-+ total, TEM CD8+IFN-+, TEM CD8+IFN-+ total e TEMRA CD8+IFN-+ correlacionaram-se negativamente com a carga viral do HIV em pacientes virêmicos. Esses dados sugerem que essas subpopulações de memória funcionais são importantes no controle da viremia. Comparando as respostas HIV e CMVespecíficas observamos freqüências mais elevadas de células T de memória produtoras de IL-2, IFN-/IL-2 e IFN- em respostas ao pool de peptídeos do HIV. Esses dados sugerem que esse conjunto de peptídeos derivados de seqüências do HIV-1 ativa respostas polifuncionais de subpopulações de linfócitos T de memória. Nossos resultados mostraram que o conjunto de peptídeos do HIV-1 foi capaz de estimular diferentes subpopulações distintas de linfócitos T de memória produtores de IFN-, IFN-,/IL-2 e IL-2 de indivíduos em diferentes estágios da infecção pelo HIV e sugerem o envolvimento de subpopulações de memória funcionais no controle da viremia. Estes achados fortalecem a possibilidade de uso desses peptídeos em uma formulação vacinal bem-sucedida em humanos / The persistence of functional memory T cell is important to ensure a protective immunity to Human Immunodeficiency Virus (HIV) infection. Memory T cells have been subdivided into central memory (TCM), effector memory (TEM) and highly differentiated effector memory (TEMRA) based on the expression of surface molecules such as CCR7 and CD45RA, and the ability to produce cytokines and proliferate. Recently, we identified 18 peptides derived from B consensus sequences of HIV-1 that bind to multiple HLA-DR molecules and are widely recognized by peripheral blood T lymphocytes from HIV-infected patients. Given this and considering the importance of memory T cells in the maintenance of specific immune response, our objective was to characterize phenotypic and functionally memory T cell subsets from HIV-infected individuals involved in the recognition of these epitopes in vitro. The study included 14 healthy control subjects and 61 HIV+ patients with CD4+ lymphocytes counts higher than 250 cells/mm3. The HIV+ patients were divided into six different clinical groups according to the stage of infection, plasma viral load (VL) and antiretroviral therapy use (ART): long-term non-progressors (LTNP), aviremic under ART (AV-ART), viremic under ART (VI-ART), viremic without using ART (VI without ART), recently infected viremic without using ART (VI-RI) and controllers. Peripheral blood mononuclear cells from study subjects were stimulated with HIV-1 peptide pool and with a cytomegalovirus (CMV) peptide pool. The frequencies of IFN- and IL-2 producing memory cells and antigenspecific cell proliferation were detected by multiparametric flow cytometry. Our results showed that the HIV-1 set of peptides was able to activate TCM, TEM and TEMRA functional memory subsets that secrete IFN- and IL-2 in 100% of the HIV patients from the different clinical groups. The HIV-1 set of peptides also induced memory T lymphocyte subsets proliferation. TEMRA CD4+IFN-+, total TEMRA CD4+IFN-+, TCM CD8+IFN-+, total TCM CD8+IFN-+, total TEM CD8+IFN-+, TEM CD8+IFN-+ and TEMRA CD8+IFN- + frequencies negatively correlated with HIV viral load in viremic patients. These data suggest that these functional memory subsets are important to control the viremia. When comparing the HIV and CMV-specific responses we observed higher frequencies of IL-2, IFN-/IL-2 and IFN- producing memory T cells in response to HIV peptide pool. These data suggest that this set of HIV sequence derived peptides activates polyfunctional response of memory T lymphocyte subsets. Our results showed that the HIV-1 peptide set was able to stimulate different IFN-, IFN-/IL-2 e IL-2 producing memory T lymphocytes from individuals in different stages of HIV infection and suggest the involvement of functional memory subsets in the control of viremia. These findings strengthen the possibility of using these peptides in a successful vaccine formulation in humans
|
46 |
Imunogenicidade de vacinas de DNA codificando peptídeos conservados e promíscuos do HIV-1, em camundongos BALB/c / Immunogenicity of DNA vaccines encoding conserved and promiscuous HIV-1 peptides, in BALB/c miceAlmeida, Rafael Ribeiro 10 June 2011 (has links)
A pandemia de AIDS é um dos principais problemas de saúde pública no mundo e demanda o desenvolvimento de uma vacina eficaz. Uma abordagem vacinal ideal, baseada em resposta celular contra o HIV-1, deveria induzir uma resposta imune mediada tanto por células T CD4+ quanto CD8+. A diversidade genética do HIV-1 é uma grande preocupação para o desenvolvimento de uma vacina e sequências consenso têm sido utilizadas a fim de contornar a barreira imposta por essa diversidade. A escolha apropriada dos antígenos a comporem as construções vacinas também é relevante, visto que proteínas como Gag e Vif têm se mostrado bastante imunogênicas, enquanto alguns trabalhos têm demonstrado que Env possui características imunossupressoras e que respostas celulares contra esse antígeno podem ser danosas aos indivíduos vacinados. Nosso grupo demonstrou que uma vacina de DNA (HIVBr18) codificando 18 peptídeos para linfócitos T CD4+, promíscuos (capazes de se ligarem a múltiplas moléculas HLA-DR) e conservados na sequência consenso do subtipo B do HIV-1 foi capaz de induzir uma resposta celular ampla, polifuncional e de longa duração em camundongos BALB/c e transgênicos para moléculas HLA. Neste trabalho identificamos 34 peptídeos potencialmente reconhecidos por linfócitos T CD4+, promíscuos e conservados na sequência consenso dos consensos do grupo M do HIV-1. Uma vacina de DNA (HIVBr27) codificando 27 dos 34 peptídeos (exceto os 7 peptídeos de Env identificados) induziu uma resposta mais ampla e de maior magnitude que a vacina HIVBr18 em camundongos BALB/c. Além disso, a vacina HIVBr27 induziu maior frequência de linfócitos T CD4+ e CD8+ polifuncionais, capazes de proliferar e produzir as citocinas IFN-gama e TNF-alfa. Desenvolvemos também uma vacina de DNA (HIVenv7) codificando os 7 peptídeos de Env do HIV-1 identificados. A co-imunização de HIVenv7+HIVBr27 reduziu a amplitude da resposta celular contra peptídeos codificados pela vacina HIVBr27. Além disso, a co-imunização reduziu a magnitude da resposta e a frequência de linfócitos T CD4+ e CD8+ polifuncionais contra o pool de 27 peptídeos codificados por essa vacina. A vacina HIVBr27, desenhada para induzir uma resposta de linfócitos T CD4+ ampla e intensa contra peptídeos promíscuos e conservados da sequência consenso dos consensos do grupo M do HIV-1, é mais imunogênica e mais completa que a vacina HIVBr18, tendo potencial de conferir, em grande cobertura populacional, imunidade contra os diversos subtipos circulantes do vírus. O fenômeno observado na co-imunização com HIVenv7 sugere que a inclusão do envelope em imunógenos contra o HIV-1 possa ser prejudicial. Por outro lado, isto faz desse plasmídeo um alvo promissor para terapias imunológicas que visem indução de imunossupressão / The AIDS pandemic is a worldwide major public health problem and requires the development of an effective vaccine. An ideal vaccine approach based on cellular immune responses against HIV-1 should induce an immune response mediated by both CD4+ and CD8+ T cells. HIV-1 genetic diversity is a major concern for developing a vaccine and consensus sequences have been used to circumvent the barrier posed by this diversity. The appropriate choice of antigens to compose the vaccines is also relevant, since proteins such as Gag and Vif have been shown to be immunogenic, while some studies have shown that Env has immunosuppressive characteristics and cellular responses against this antigen can be harmful to vaccinated individuals. Our group has demonstrated that a DNA vaccine (HIVBr18) encoding promiscuous multiple HLA-DR binding, conserved B-subtype HIV-1 CD4+ T cell epitopes was able to induce a broad, polyfunctional and long lasting T cell response in BALB/c and HLA transgenic mice. In this work we identified 34 promiscuous and conserved sequences within the group M HIV-1 consensus of the consensus sequence, potentially recognized by CD4+ T cells. A DNA vaccine (HIVBr27) encoding 27 of the 34 peptides (except the 7 Env identified peptides) induced a broader and higher magnitude T cell response than HIVBr18 vaccine in BALB/c mice. Moreover, the vaccine HIVBr27 induced a higher frequency of polyfunctional CD4+ and CD8+ T cells, able to proliferate and produce the cytokines IFN-gama and TNF-alfa. We also developed a DNA vaccine (HIVenv7) encoding the 7 HIV-1 Env identified peptides. Co-immunization with HIVenv7+HIVBr27 reduced the breadth of the cellular immune response against the HIVBr27 encoded peptides. Besides, co-imunization reduced the magnitude of the response and the frequency of polyfunctional CD4+ and CD8+ T cells against the pool of 27 peptides encoded by this vaccine. The HIVBr27 vaccine, designed to induce a broad and intense CD4+ T cell response against promiscuous and conserved peptides within the group M HIV-1 consensus of the consensus sequence, is more immunogenic and more complete than the vaccine HIVBr18, having the potential to provide, with wide population coverage, immunity against various circulating subtypes of the virus. The phenomenon observed in the co-immunization with HIVenv7 suggests that the inclusion of the envelope in immunogens against HIV-1 may be harmful. On the other hand, these results suggest that HIVenv7 is a promising target for immune therapies aimed at inducing immunosuppression
|
47 |
Análise do perfil transcricional de células dendríticas derivadas de monócitos utilizadas na vacina terapêutica anti-HIV-1 / Transcription profile of monocyte derived dendritic cells used in therapeutic HIV-1 vaccine modelOliveira, Rafael Martins de 27 May 2010 (has links)
Aplicando tecnologia de microarray, objetivamos traçar o perfil do programa de maturação das Mo-DC pulsadas com HIV autólogo inativado por AT-2, a fim de identificar marcadores específicos de ativação funcional e sugerir um perfil de expressão de genes úteis na identificação de respostas ao modelo in vitro das Mo-vacina DC. Essas informações podem ajudar a estabelecer assinaturas moleculares das funções celulares mais relevante para a melhoria das vacinas terapêuticas. O perfil transcricional foi analisado com base das vias celulares moduladas das Mo-DCs no estado imaturo, transitório e maduro. O HIV-1 inativado por AT-2 induz ativação de genes associados à apresentação de antígenos. Os conjuntos de genes do citoesqueleto podem influenciar a mudança de comportamento migratório das Mo-DCs ativadas. O aumento na expressão dos receptores celulares contribuem para o recrutamento de monócitos, DCs e macrófagos para o local da infecção. Além disso, modulam a resposta imune inata e adaptativa, incluindo a polarização das células Th e sub-regulação da resposta inflamatória, que pode interferir significativamente com a resposta imune. Coletivamente, o perfil transcricional das Mo-DCs induzido pelo HIV-1 inativado com AT-2 reflete uma significativa reprogramação imunológica e celular das células envolvidas na resposta imune do hospedeiro. Os resultados deste estudo focaram na interpretação de genes específicos dos perfis de transcrição das Mo-DCs como modelo terapêutico utilizado na vacina anti-HIV. As análises de assinaturas gene associado e sua correlação as respostas funcionais simplificam a identificação de indivíduos susceptíveis a vacina e a compreensão de eventuais falhas em ensaios clínicos. Microarray permitiu a análise quantitativa e simultânea da expressão de um elevado número de genes. Os estudos do perfil de expressão foram extremamente úteis para identificar os eventos moleculares e vias envolvidas nas funções de celular induzida por estímulos específicos. Em particular, os resultados sobre o padrão global da expressão dos genes subjacentes as modificações induzidas pelo HIV-1 inativado por AT-2, na fase inicial da administração do antígeno, pôde ser extremamente útil para a identificarmos marcadores de ativação e avaliar os efeitos biológicos que poderiam estar envolvidos para modificação e otimização de estratégias vacinação com Mo-DC / Applying microarray technology, we intend to profile the program to mature Mo-DC pulsed with autologous inactivated HIV by AT-2, in order to identify specific markers of functional activation and suggest a profile of expression of specific genes, useful identification of responders to in vitro model of Mo-DC vaccine. Such information may help to establish detailed molecular signatures of cellular functions most relevant to improving the therapeutic vaccines. The transcriptional profile was analyzed on the basis of the cellular pathways modulated in immature MoDC, transitional MoDC and mature MoDC. The AT-2-inactivated HIV-1 induction of MoDC results in the activation of genes associated with antigen presentation functions. A set of cytoskeletal genes that may potentially mediate shape change and migratory behavior of activated MoDC is also observed. The increase in the expression of immune receptors contribute to the recruitment of monocytes, DCs, and macrophages to the site of infection. Moreover, they modulate both innate and adaptive immune response, including the polarization of Th cells, and the down-regulation of the inflammatory response, which may significantly interfere with the immune response. Collectively, the transcriptional profile induced by AT-2-inactivated HIV-1 in MoDc reflects a significant cellular and immunological reprogramming of cells directly involved in the host immune response. The results of this study focused on the interpretation of specific genes of transcription profile of MoDC used in therapeutic HIV vaccine model. Supplementing the analyses with examination of associated gene signatures and their correlation to functional responses will simplify the identification of responsive vaccine individuals and the understanding of eventual failures in individuals enrolled in clinical trials. Microarray approach allows quantitative and simultaneous analysis of gene expression of a large amount of genes and the systematic studies of expression patterns are extremely useful for identify molecular events and key pathways involved in cellular functions induced by specific stimuli. In particular, data on the global pattern of gene expression underlying the modifications induced by AT-2-inactivated HIV-1 in MoDC, at early stages of antigen administration, may be extremely helpful for the identification of exclusive activation markers to trace the biological effects of modifications/optimizations of the MoDc vaccination strategy
|
48 |
Estudo de fase I/II de uma terapia celular para HIV baseada em células dendríticas autólogas pulsadas com vírus autólogos quimicamente inativados / Phase I / II study of cellular therapy for HIV based on autologous dendritic cells pulsed with autologous chemically inactivated virusAlmeida, Alexandre de 22 May 2017 (has links)
Desde o início da pandemia de HIV/aids, a imunoterapia vem sendo utilizada como alternativa terapêutica numa tentativa de estimular uma resposta do sistema imunológico contra o agente agressor. Esta abordagem tem sido considerada promissora para obtenção do controle da infecção em longo prazo. A administração de células apresentadoras de antígeno, em especial células dendríticas, é fundamentada pelos conceitos de imunoterapia passiva e de terapia celular ativa (vacina terapêutica) além da perspectiva da eliminação dos chamados reservatórios virais, unindo assim estas diversas estratégias de intervenção. Dentre os diferentes antígenos do HIV utilizados para pulsar as células dendríticas, alguns dos melhores resultados foram obtidos com a inativação química do vírus, preservando a integridade da estrutura da sua superfície.Há alguns anos nosso grupo vem trabalhando com terapia celular baseada em células dendríticas derivadas de monócitos autólogos, pulsadas com HIV inativado quimicamente, seguindo o protocolo descrito por Lu e colaboradores em 2004. Aqui, nós apresentamos os resultados de um ensaio clínico de fase I/II que teve como objetivos avaliar a tolerância, segurança e impacto imunovirológico, de diferentes formulações do produto em pacientes cronicamente infectados pelo HIV, sem uso de antirretrovirais. Os participantes foram alocados em três braços para receber composições distintas: 3x107 células dendríticas sem pulso adicional de HIV inativado (Braço A), 3x106 células dendríticas com pulso adicional de HIV inativado (Braço B) ou 3x107 células dendríticas com pulso adicional de HIV inativado (Braço C). O número de participantes no braço A evoluiu com uma considerável diminuição ao longo do período de observação do estudo, prejudicando as avaliações. As análises dos outros braços mostraram que as preparações foram seguras, não se observando eventos adversos relacionados à intervenção. Os resultados sugeriram um aumento na carga viral plasmática associados a uma redução das sub-populações de linfócitos TCD4+ e TCD8+ nos pacientes do braço C além de uma redução na quantidade de linfócitos T reguladores nos indivíduos do braço B / Since the beginning of the HIV / aids pandemic, immunotherapy is being used as an alternative therapy in attempt to stimulate an immune response against the pathogenic agent. This approach has been considered as promising for achieving the control of infection in the long term. Administration of antigen presenting cells, particularly dendritic cells is based on the concepts of passive immunotherapy and active cellular therapy (therapeutic vaccine), with the perspective of eliminating the so-called viral reservoirs, thus joining different intervention strategies. From different antigens tested for loading DCs, some of the best results were obtained with chemically inactivated virus, which preserves its surface proteins.Our group has been working with cellular therapy based on dendritic cells derived from autologous monocytes pulsed with chemicallyinactivatedHIV, following the protocol described by Lu et al in 2004.Here, we present the results of a phase I / II clinical trial aimed to evaluate tolerance, safety and immunovirological impact of different product formulations in chronically HIV-infected individuals, naïve for antiretroviral treatment.Participants were allocated to receive: 3x107 un-pulsed DCs (Arm A), 3x106 HIV-pulsed DCs (Arm B) or 3x107 HIV-pulsed DCs (Arm C). The number of participants in the arm A evolved with a considerable decrease over the study, so any considerations about effect of DCs without antigen overload were difficult to carry out. Outcomes in other arms showedthat they were safe, with no adverse events related to the products. The results suggested an increase in plasma viral load and decline in CD4+ and CD8+ T cells subpopulations after intervention in arm C. Additionally, we observed a decrease in percentage of regulatory T cells in arm B patients
|
49 |
Análise do perfil transcricional de células dendríticas derivadas de monócitos utilizadas na vacina terapêutica anti-HIV-1 / Transcription profile of monocyte derived dendritic cells used in therapeutic HIV-1 vaccine modelRafael Martins de Oliveira 27 May 2010 (has links)
Aplicando tecnologia de microarray, objetivamos traçar o perfil do programa de maturação das Mo-DC pulsadas com HIV autólogo inativado por AT-2, a fim de identificar marcadores específicos de ativação funcional e sugerir um perfil de expressão de genes úteis na identificação de respostas ao modelo in vitro das Mo-vacina DC. Essas informações podem ajudar a estabelecer assinaturas moleculares das funções celulares mais relevante para a melhoria das vacinas terapêuticas. O perfil transcricional foi analisado com base das vias celulares moduladas das Mo-DCs no estado imaturo, transitório e maduro. O HIV-1 inativado por AT-2 induz ativação de genes associados à apresentação de antígenos. Os conjuntos de genes do citoesqueleto podem influenciar a mudança de comportamento migratório das Mo-DCs ativadas. O aumento na expressão dos receptores celulares contribuem para o recrutamento de monócitos, DCs e macrófagos para o local da infecção. Além disso, modulam a resposta imune inata e adaptativa, incluindo a polarização das células Th e sub-regulação da resposta inflamatória, que pode interferir significativamente com a resposta imune. Coletivamente, o perfil transcricional das Mo-DCs induzido pelo HIV-1 inativado com AT-2 reflete uma significativa reprogramação imunológica e celular das células envolvidas na resposta imune do hospedeiro. Os resultados deste estudo focaram na interpretação de genes específicos dos perfis de transcrição das Mo-DCs como modelo terapêutico utilizado na vacina anti-HIV. As análises de assinaturas gene associado e sua correlação as respostas funcionais simplificam a identificação de indivíduos susceptíveis a vacina e a compreensão de eventuais falhas em ensaios clínicos. Microarray permitiu a análise quantitativa e simultânea da expressão de um elevado número de genes. Os estudos do perfil de expressão foram extremamente úteis para identificar os eventos moleculares e vias envolvidas nas funções de celular induzida por estímulos específicos. Em particular, os resultados sobre o padrão global da expressão dos genes subjacentes as modificações induzidas pelo HIV-1 inativado por AT-2, na fase inicial da administração do antígeno, pôde ser extremamente útil para a identificarmos marcadores de ativação e avaliar os efeitos biológicos que poderiam estar envolvidos para modificação e otimização de estratégias vacinação com Mo-DC / Applying microarray technology, we intend to profile the program to mature Mo-DC pulsed with autologous inactivated HIV by AT-2, in order to identify specific markers of functional activation and suggest a profile of expression of specific genes, useful identification of responders to in vitro model of Mo-DC vaccine. Such information may help to establish detailed molecular signatures of cellular functions most relevant to improving the therapeutic vaccines. The transcriptional profile was analyzed on the basis of the cellular pathways modulated in immature MoDC, transitional MoDC and mature MoDC. The AT-2-inactivated HIV-1 induction of MoDC results in the activation of genes associated with antigen presentation functions. A set of cytoskeletal genes that may potentially mediate shape change and migratory behavior of activated MoDC is also observed. The increase in the expression of immune receptors contribute to the recruitment of monocytes, DCs, and macrophages to the site of infection. Moreover, they modulate both innate and adaptive immune response, including the polarization of Th cells, and the down-regulation of the inflammatory response, which may significantly interfere with the immune response. Collectively, the transcriptional profile induced by AT-2-inactivated HIV-1 in MoDc reflects a significant cellular and immunological reprogramming of cells directly involved in the host immune response. The results of this study focused on the interpretation of specific genes of transcription profile of MoDC used in therapeutic HIV vaccine model. Supplementing the analyses with examination of associated gene signatures and their correlation to functional responses will simplify the identification of responsive vaccine individuals and the understanding of eventual failures in individuals enrolled in clinical trials. Microarray approach allows quantitative and simultaneous analysis of gene expression of a large amount of genes and the systematic studies of expression patterns are extremely useful for identify molecular events and key pathways involved in cellular functions induced by specific stimuli. In particular, data on the global pattern of gene expression underlying the modifications induced by AT-2-inactivated HIV-1 in MoDC, at early stages of antigen administration, may be extremely helpful for the identification of exclusive activation markers to trace the biological effects of modifications/optimizations of the MoDc vaccination strategy
|
50 |
An exploratory study of students' understandings and experiences of vaccination : implications for future HIV vaccine trials in South Africa.Masina, Liziwe N. V. January 2004 (has links)
As Africa faces the challenges of its renewal or renaissance, the HIV/AIDS epidemic poses the greatest potential barrier to the attainment of this vision (Makgoba, 2001 in Dorrington, Bourne, Bradshaw, Laubscher & Timaeus, 2001). The development of an HIV vaccine that is safe, effective and affordable, has been widely contemplated as a necessary supplement to already established interventions. In preparation for HIV vaccine trials in South Africa the current project aimed to assess students' understanding (knowledge and perceptions) and experiences of vaccination in general, and to explore if these were associated with demographics such as motherhood and gender. A parallel aim was to assess students' knowledge and expectations of HIV vaccination and trial participation. A sample of 33 students was recruited from university residences at the University of Natal, Pietermaritzburg. Participants were interviewed via a semi-structured interview schedule. The data collected was then coded and analysed using content analysis, while Chi - square analysis was used to evaluate if demographics such as gender and motherhood were systematically associated with various responses. The results revealed that the vast majority of participants (97%) knew the purpose of vaccination, stating that it was to promote health and prevent illness. Most participants (67%) knew that vaccination works by mobilising the immune system (vaccination mechanism). The vast majority of participants (91%) could name at least one vaccine preventable disease. Uptake of childhood immunisation was reportedly high (88%) while adult uptake of immunisation was low (33%). A significant minority (36%) reported that they had experienced side effects but understood these to be an integral part of vaccination. Thirty percent of participants stated they were willing to participate (WTP) in a hypothetical vaccine trial, 33 % of participants were not WTP and 15% were not sure. Motivations for trial participation were reportedly influenced most by personal incentives of altruism (39%) and barriers such as perceived significant physical risk (61%). In general, knowledge and experiences of vaccination were not associated with gender or with motherhood. The results suggest that more awareness of HIV vaccine trials is needed. In this regard education should emphasise that the prospective vaccine will be preventive, that only healthy people can volunteer and that the HIV vaccine will not guarantee immunity to HIV infection. Suggestions are made for future research into motivations, barriers and incentives to facilitate an ethical process of vaccine trial participation. / Thesis (M.Soc.Sc.)-University of KwaZulu-Natal, Pietermaritzburg, 2004.
|
Page generated in 0.133 seconds